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ABSTRACT: To combat the rise of antimicrobial resistance, the discovery of new antibiotics is paramount. Albicidin and cys-
tobactamid are related natural product antibiotics with potent activity against Gram-positive and, crucially, Gram-negative 
pathogens. AlbA has been reported to neutralize albicidin by binding it with nanomolar affinity. To understand this potential 
resistance mechanism, we determined structures of AlbA and its complex with albicidin. The structures revealed AlbA to be 
comprised of two domains, each unexpectedly resembling the multi-antibiotic neutralizing protein TipA. Binding of the long 
albicidin molecule was shared pseudosymmetrically between the two domains. The structure also revealed an unexpected 
chemical modification of albicidin, which we demonstrate to be promoted by AlbA, and to reduce albicidin potency; we pro-
pose a mechanism for this reaction. Overall, our findings suggest that AlbA arose through internal duplication in an ancient 
TipA-like gene, leading to a new binding scaffold adapted to the sequestration of long-chain antibiotics. 
Introduction 
Natural products continue to be an abundant source of 
novel and biologically active molecules (e.g.1). The majority 
of drugs currently on the market to treat bacterial infections 
are natural products and their derivatives – they have be-
come a major pillar of modern medicine and are regarded 
as essential for human health2. With the extensive use of an-
tibiotics, however, the problem of (multi-)resistance devel-
opment in human pathogens has risen3. To keep pace with 
resistance development and always have effective antibiot-
ics available, constant antibiotic discovery and optimization 
efforts are required; a challenge that was not met in the past 
decades4. Most problematic with regard to drug develop-
ment are Gram-negative pathogens, which are becoming a 
severe threat to public health5. Multidrug resistance (MDR) 
mechanisms pose a particular challenge, since such systems 
are able to recognize and neutralize structurally and chem-
ically diverse compounds, while still being selective for a 
certain compound class6. 
Antibiotic resistance usually results from one of four 
mechanisms: Modification of the bacterial cell wall to pre-
vent antibiotic entry, expulsion of the antibiotic by general 
or specific efflux pumps, mutation of the cellular target, or 
chemical modification of the antibiotic7-8. These mecha-
nisms (with the exception of target mutations) are often 
employed after bacterial antibiotic-specific biosensors bind 
to an antibiotic and subsequently trigger transcriptional 
programs9-10. One protein class involved in such processes 
are thiostrepton-induced protein A (TipA) systems11-12. 
TipA belongs to the superfamily of mercuric ion resistance 
(MerR) -like transcriptional regulators12-14, which contain 
an N-terminal helix-turn-helix (HTH) motif, followed by a 
coiled-coil region and a C-terminal effector binding do-
main15-17. The tipA gene contains two alternative start co-
dons, giving rise to TipA-L and TipA-S protein isoforms (Fig-
ure 1A)17-18. 
Figure 1 A Basic logic of the TipA system. The tipA gene con-
tains two alternative start codons giving rise to TipA-L and 
TipA-S, which are identical in their C-terminal domains. While 
TipA-S scrubs free antibiotic from the cytoplasm, TipA-L di-
merizes after ligand binding and induces increased expression 
from the tipA gene. B Chemical structures of albicidin (1) and 
cystobactamid 919-2 (7). 
While TipA-L follows the basic MerR architecture, TipA-S 
is the predominant form and consist only of the effector 
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binding domain11-12, 17, 19. This domain is able to covalently 
bind a wide variety of thiopeptide antibiotics via an active 
site cysteine12, 15-16 and thus permanently sequester the an-
tibiotics16. Upon substrate binding, TipA-L forms a dimer, 
which then binds to promotors via its HTH domain and in-
duces the transcription of multiple genes, including tipA, 
which can thus be viewed as a minimal autoregulated MDR 
system11. Recently reported NMR-based structural studies 
of TipA-S allowed the proposition of a model for how this 
protein is able to neutralize a wide variety of thiopeptide 
antibiotics15-16: Upon thiopeptide binding TipA-S transi-
tions from a partially unstructured to a fully ordered state16. 
In the process, a large substrate binding cleft is formed that 
contains the active-site cysteine, which reacts with the 
bound substrate to form a covalent bond16. 
The natural products albicidin (1) and cystobactamid (7) 
(Figure 1B) were reported as potent anti-Gram-negative an-
tibiotics with minimal inhibitory concentrations (MICs) in 
the sub-µg/mL range against Escherichia coli and other rel-
evant pathogens20-21. Albicidin is produced by the plant 
pathogen Xanthomonas albilineans22-24, and was found to be 
a strong inhibitor of DNA gyrase in Gram-negative bacteria 
(E. coli)25. The unusual structure of albicidin was reported 
in 2015: It consists of p-aminobenzoic acid (PABA) building 
blocks and cyanoalanine as a central unnatural amino acid 
(Figure 1B)26. Concurrently, cystobactamids, produced by 
myxobacteria, were discovered as a novel class of antibiot-
ics that address the same bacterial target and possess a sim-
ilar structure (Figure 1B)21. Several differences between the 
two compound classes exist: While the N-terminus of cysto-
bactamids consists of a p-nitro-benzoic acid, the equivalent 
position in albicidin is occupied by 2-methyl-p-coumaric 
acid. Additionally, the two C-terminal building blocks in cys-
tobactamid 919-2 are isopropoxylated in the 3-position, 
whereas albicidins are methoxylated, and the C-terminal 
building block of cystobactamide 919-2 lacks hydroxylation 
in the 2-position. Finally, the most potent cystobactamids 
have a central -methoxy-asparagine amino acid instead of 
the cyanoalanine found in the original albicidin. 
Since antibiotics such as albicidin and cystobactamids oc-
cur naturally, resistance mechanisms have already been de-
veloped. Three proteins have been reported as resistance 
proteins against albicidin: AlbA, AlbB and AlbD18, 27-28. AlbA 
is a distant member of the TipA family and can be found in 
a variety of Klebsiellae strains including the problematic hu-
man pathogen K. pneumoniae. Earlier studies of AlbA re-
ported the protein to bind albicidin at a single high-affinity 
binding site with low nM affinity and that ligand-binding in-
duced major conformational changes29-30. Additionally, an 
alanine scan of AlbA identified several key residues in-
volved in albicidin binding29 and it has been suggested that 
AlbA confers albicidin resistance by removing free albicidin 
from the cell18, 31. During the evaluation of our manuscript, 
parallel work by Rostock et al. was published26. The very 
thorough biophysical characterization of the AlbA-albicidin 
interaction using NMR and fluorescence spectroscopy, as 
well as the crystal structure of the AlbA-albicidin complex 
were reported. In addition, AlbA was found to protect the 
albicidin target DNA gyrase from the antibiotic and several 
derivatives in vitro and bacterial cells in an agar diffusion 
assay26. 
Here, we report the crystal structures of both, AlbA and 
its complex with albicidin. Unexpectedly, we found AlbA to 
promote a chemical reaction in albicidin slowly, leading to 
a loss of biological activity that redefines our understanding 
of AlbA-mediated albicidin resistance. We provide detailed 
mutational studies, which allowed us to propose a mecha-
nism for this reaction. We used the structural data to con-
duct a comprehensive analysis of the prevalence of AlbA-
like genes in important human pathogens and their evolu-
tionary development. Finally, we demonstrate that AlbA ex-
pression is upregulated in K. pneumoniae upon treatment 
with albicidin. 
Results 
AlbA is a structural homolog of TipA-S 
To understand how AlbA may exert its function, we deter-
mined its high-resolution crystal structure. The full-length 
wild-type AlbA (AlbAwt) protein from K. oxytoca (see mate-
rials and methods for details) formed crystals belonging to 
space-group P43212 and the structure was determined at 
1.9 Å resolution by single-wavelength anomalous disper-
sion using selenomethionine (PDB ID 6h95). All data collec-
tion and refinement statistics can be found in table S1. The 
refined model contained one AlbAwt molecule in the asym-
metric unit and includes residues 1 – 221 (Figure 2A). It is 
an -helical protein with a flattened, oblong shape measur-
ing approximately 60 Å x 40 Å x 25 Å. AlbAwt has no se-
quence homologs in the protein data bank (PDB), and we 
therefore searched for structural homologs using the DALI 
server32. No protein was found to cover more than 50 % of 
the AlbAwt structure, but upon closer inspection it became 
apparent that the fully ordered (ligand bound) structure of 
TipA-S (PDB 2mc0) aligns to the N-terminal 114 residues of 
AlbAwt (C rmsd of 3.7 Å, sequence identity 15 %) and that 
an additional copy of the same TipA-S structure also aligns 
to AlbAwt residues 115 – 216 (C rmsd of 3.9 Å, sequence 
identity 16 %) (Figure 2B and S1). Following TipA-S nomen-
clature15-16 (TipA-S consists of helices 6 - 13), AlbAwt does 
not contain 6, but all other helices are largely conserved. 
Helices 7 and 8, which are critical for substrate binding 
in TipA-S15-16, are much shorter in AlbAwt and do not form 
the deep substrate binding cleft observed in TipA-S15-16. 
Best conservation (helix length and relative position) is ob-
served for 9 and 10. Intriguingly, unlike TipA-S, 11 and 
13 of AlbAwt are neither parallel nor in direct contact with 
each other, but spread apart (Figure 2C). In AlbAwt, helix 
13 is significantly longer than in TipA-S and its C-terminal 
portion aligns with 7 of the second TipA-S copy (TipA-S’) 
(Figure 2B and S1). The alignment of TipA-S’ 8 - 13 with 
AlbAwt 8’ to 13’ corresponds to the alignment of TipA-S 
with the N-terminal half of AlbAwt. It thus appears that AlbA 
originated from an internal gene duplication event in a 
TipA-S-like gene, giving rise to a pseudosymmetric TipA-S 
dimer. In addition to the change in binding-site architecture, 
the residues identified as important for substrate binding, 
including the active-site cysteine, show no conservation. In 
TipA, the cysteine reacts with dehydroalanine residues 
when TipA-S/L bind thiopeptide antibiotics to form cova-
lent complexes12, 33, chemistry which would not be possible 
with albicidin. Binding of albicidin must therefore follow a 
different logic, and we identified a putative substrate bind-
ing tunnel, which runs across the entire length of the 
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protein (Figure S2). Its formation is a direct result of the 
movements of helices 11 / 13 and 11’ / 13’ (Figure 
S3). 
Structure of the AlbAwt -albicidin complex 
In order to understand how albicidin may fit into the pu-
tative substrate binding tunnel of AlbA we determined the 
high-resolution structure of the AlbAwt-albicidin complex. 
The natural product albicidin was synthesized according to 
a previously published procedure (see supplementary 
online material)20. 
Figure 2 A Overall structure of AlbAwt. The structure of AlbAwt is shown in cartoon representation using the rainbow color scheme 
(N-terminus blue, C-terminus red). B AlbA is a tandem repeat of TipA-S. The AlbAwt structure is shown as a cartoon representation 
with the N-terminal TipA-S repeat in green, and the C-terminal TipA-S repeat in blue. Helices that underwent a drastic change in 
orientation and relative position in AlbAwt (when compared to TipA-S) are labeled. A secondary structure diagram shows the con-
servation of helix length and position between the two proteins. C AlbAwt-albicidin complex structure. Protein representation and 
color scheme as in B. Albicidin is represented as sticks. Carbon atoms black, oxygen atoms red, nitrogen atoms blue, unassigned atom 
cyan. The difference electron density (Fo – Fc contoured at 3σ with phases calculated from a model which was refined with no albi-
cidin present) is shown as a grey isomesh. D Chemical structures of the two possible albicidin conversion products, the primary 
ketimine 2 and the succinimide 3. 
AlbAwt was incubated with an excess of albicidin and sub-
sequently crystallized in space group C2221. The structure 
was determined to 1.55 Å resolution by molecular replace-
ment using the structure of AlbAwt as a search model (PDB 
ID 6h96). 
The new crystal form contained two AlbAwt monomers in 
the asymmetric unit and the overall structure of AlbAwt is 
virtually unchanged after binding albicidin (Rmsd of 0.8 Å 
over all non-hydrogen atoms, Figure S4). It has been re-
ported that the NMR spectra of AlbA show extensive line-
broadening in the absence of albicidin, which may be caused 
by slow internal dynamics of the protein26. This observation 
led to the hypothesis that AlbA may exist in an open and 
closed conformation, with an ensemble of intermediate 
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states26. Since the AlbA structure we determined corre-
sponds to the AlbA-albicidin complex structure, we suggest 
that we have crystallized the closed conformation of the 
protein. We observed clear and unambiguous electron den-
sity for albicidin, spanning the entire length of AlbA (Figure 
2A and S5), with binding of the extended albicidin molecule 
shared pseudosymmetrically between the two TipA-S do-
mains. Upon closer inspection of the electron density for the 
ligand, it became obvious that the central cyanoalanine moi-
ety had cyclized to yield a five-membered ring, in which the 
nitrile group had been converted to a primary ketimine or 
succinimide (2 and 3, respectively, Figures 2D and S5). 
Equivalent electron density was also reported by Rostock et 
al. (PDB ID 6et8)26, but an unmodified albicidin molecule 
was built into the density, which resulted in a poor fit, high 
B-factor of the nitrile carbon compared to adjacent atoms 
and very close interatomic distance between the amide pro-
ton of NH25 (numbering in Figure 2D) and the triple bond 
of the nitrile moiety (1.4 Å) (Figure S5). Albicidin is almost 
completely buried in the AlbA tunnel and engages in exten-
sive hydrophobic interactions. A complete LigPlot interac-
tion diagram can be found in Figure S6. Several residues 
identified previously as important for albicidin binding 
through an alanine scan29 are in fact in contact with albi-
cidin. In addition to the hydrophobic interactions, AlbA and 
albicidin form a salt-bridge and several hydrogen bonds, all 
mediated by side-chains. The carbonyl oxygen O13 (num-
bering in Figure 2D) forms a hydrogen bond with H78, while 
N75 is a bidentate ligand, forming hydrogen bonds with 
NH21 (immediately adjacent to the five-membered ring) 
and O26 (part of the newly formed ring). The ketimine / ke-
tone moiety (NH / O62) is hydrogen bonded to T99, and the 
final interactions concern the terminal para-aminobenzoic 
acid unit. The side-chain of Y169 is hydrogen-bonded to 
O56 (methylated m-oxygen), while Q205 and R181 form a 
hydrogen bond and salt bridge, respectively, with the termi-
nal carboxyl group. These extensive interactions explain the 
high affinity of AlbAwt for albicidin. 
AlbAwt promotes the cyclization of albicidin 
We wondered whether the observed five-membered ring 
was an artefact or an AlbA-mediated modification of albi-
cidin. When equimolar amounts of AlbAwt and albicidin (100 
µM each) were incubated at 37 °C for 24 h prior to analysis 
by high-resolution liquid chromatography-mass spectrom-
etry (HR-LCMS), we discovered that the AlbAwt-albicidin 
sample contained four additional peaks (Figure 3A). In con-
trast, control samples set up in the reaction buffer with BSA 
(Figure S7) or without protein (Figure 3A) showed no con-
version of albicidin. In fact, only traces of converted albi-
cidin could be detected in reaction buffer without protein 
after 14 days at 37 °C (Figure S7). This reaction was temper-
ature-dependent – after 24 h, no conversion was observed 
at 4 °C, while little conversion was detected at 20 °C. At 37 
°C, more than half of the albicidin was converted (Figures 
3A and S8). 
In the AlbAwt-containing sample, the peak representing 
albicidin (m/z calc: 843.2620, observed: 843.2621, ppm 
0.1) had decreased significantly, while two new main peaks 
appeared. The most abundant species was an isotopomer of 
albicidin with a different retention time, indicating 2 (m/z 
calc: 843.2620, observed: 843.2632, ppm 1.4), which was 
supported by tandem mass spectrometry (MS2, Figure S9). 
Since primary ketimines are unstable in aqueous solution, 
we expected the third main peak to be the hydrolysis prod-
uct of 2, the succinimide 3 (m/z calc: 844.2461, observed: 
844.2466, ppm 0.6), and the identity of 3 was in agree-
ment with MS2 data (Figure S10). The two minor peaks had 
near identical masses, and we assigned them as two dia-
stereomers of the intermediate between 2 and 3, corre-
sponding to a hemiaminal 4 (m/z calc: 861.2726, observed: 
4a 861.2740, ppm 1.6 and 4b 861.2738, ppm 1.4). While 
it is not possible to determine which peak corresponds to 
which diastereomer, MS2 data corroborated the assigned 
identity of the compounds (Figures S11 and S12). To ascer-
tain whether 2 or 3 was found in the AlbAwt-albicidin com-
plex structure, we harvested multiple AlbA-albicidin crys-
tals, washed them thoroughly and dissolved them in ace-
tonitrile prior to MS analysis. The predominant species was 
2, with a small fraction of 3 that is likely the result of hydrol-
ysis during analysis of the sample and traces of 1 (Figure 
S8). Therefore, rather than just neutralizing albicidin by 
binding to it, AlbAwt fosters the conversion of albicidin to 3, 
with 2 representing the protein-bound (and solvent-pro-
tected) intermediate. 
To better understand the albicidin conversion, we set up 
a time course experiment and observed a nearly completed 
process after 64 h when using a 1 : 1 molar ratio of protein 
and compound (Figure S13). This very slow progression 
would imply that despite the non-covalent nature of their 
interaction, cells would still have to produce stoichiometric 
quantities of AlbAwt for protection, mirroring the situation 
for TipA. When sub-stoichiometric quantities of AlbAwt 
were used, the conversion progressed very slowly, but one 
AlbAwt molecule was able to promote cyclization of multiple 
albicidin molecules (Figure S13). 
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Figure 3 A Incubation of albicidin with AlbAwt leads to the cy-
clization of albicidin at the cyanoalanine moiety. The four prod-
uct peaks were assigned to their chemical structures by MS2 
(see SOI). B Three residues are in direct contact with the newly 
formed ketimine: I95 (orange), T99 (yellow) and M131 
(brown). Their surface is represented as an isomesh with cor-
responding colors. The solid surface of albicidin is colored as 
carbon atoms black, nitrogen atoms blue, oxygen atoms red. 
The ketimine moiety is shown as a ball and stick model using 
the same color scheme. C The effects of four point- and one dou-
ble-mutant (DM, I95G/T99G) on albicidin. The 3 : 2 ratio is in-
verted for AlbAM131A when compared to the other mutants or 
wt protein. D Proposed mechanism for albicidin conversion. 
While the 2 has to be released from the protein before it can 
hydrolyze to 3, mutation of M131 to Ala or a hydrophilic resi-
due allows hydrolyzation while 2 is still bound to the protein. 
Interestingly, we also detected varying amounts of the hy-
drolysis product of 3 in samples containing substoichio-
metric AlbA concentrations, in which the central linker is ei-
ther an aspartate or iso-aspartate (m/z calc: 862.2566, ob-
served: 6 862.2569, ppm 0.3, Figure S13). Formation of 6 
is possibly the result of the extensive incubation time re-
quired and this variant of albicidin has been reported to be 
inactive34. We speculated that the relative affinities of 1 and 
2 may be a reason for slow cyclization. When we analyzed 
the interaction of AlbAwt with albicidin by surface plasmon 
resonance (SPR), the KD for this interaction was calculated 
as 2.1 nM (Figure S14), which is on par with the KD reported 
by Rostock et al.26. The main contributor to this high affinity 
was the very slow off-rate of just 1.1 x 10-4 s-1, which may 
explain the slow progression of cyclization observed at sub-
stoichiometric protein concentrations. 
The affinity of 3 was slightly weaker (11.6 nM) and, cru-
cially, 3 retained a very slow albeit slightly faster off-rate of 
2.8 x 10-4 s-1 (Figure S14). This implies very slow release of 
2/3 may be the main contributor the slow progression of 
cyclization. Overall these data therefore argue that AlbA, in 
addition to being a very strong albicidin binder, aids in the 
cyclization of albicidin. We are unaware of comparable pro-
cesses in natural products. 
Rationalizing AlbA activity 
We expected cyclization of albicidin to 2 to follow stand-
ard chemistry – deprotonation of the amide nitrogen 
(NH25), followed by nucleophilic attack on the nitrile car-
bon and subsequent protonation of the intermediate to 
yield the primary ketimine function. Since the amide nitro-
gen would be a weak nucleophile, we suspected that the re-
action may be aided by protonation of the nitrile nitrogen 
prior to nucleophilic attack, but no aspartate or glutamate 
residues were found in close proximity. To shed light on the 
reaction mechanism, we first investigated the effects of gen-
eral acid and / or base. We incubated AlbAwt with an 
equimolar amount of albicidin at different pH values from 
5.5 to 9.0 in increments of 0.5 (Figure S15). At low pH, we 
observed little cyclization, but as the pH increased, so did 
cyclization. No cyclization was observed in control reac-
tions without AlbAwt unless Tris buffer was used, in which 
case we observed slow, AlbAwt-independent cyclization of 
albicidin at pH 8.5 and 9.0 (Figure S15). While a normal pep-
tide amide would not be deprotonated under such mild con-
ditions, the amide in question can be viewed as an aniline-
derivative with a carbonyl group in the p-position, which 
presumably significantly lowers the pKa of this amide. These 
observations are suggestive of the involvement of a general 
base. 
A detailed analysis of the residues in direct contact with 
the newly formed ketimine – I95, T99 and M131 – was per-
formed (Figure 3B). The side-chain of T99 packs against the 
side-chain of I95 and is hydrogen-bonded to the ketimine. 
We thus wondered whether T99 played a role in cyclization 
and produced AlbAT99V and AlbAT99G. All mutants reported 
expressed like wild-type protein and showed highly similar 
elution profiles in size-exclusion chromatography (Figure 
S16). The overall structure of apo-AlbAT99V (PDB ID 6h97), 
determined at 2.7 Å resolution (Table S1), was unchanged 
and the mutant side-chain had the same orientation and po-
sition as T99 in the AlbAwt structure (Figure S17). When we 
tested the effect of AlbAT99V on 1, we found cyclization to be 
accelerated ~2.5 x when compared to the wt protein (Fig-
ures 3C and S18). In contrast, AlbAT99G promoted little cy-
clization, even after 24 h (Figure 3C). We thus propose that 
the side-chain of T99 creates a bottleneck in the albicidin 
binding tunnel, that forces the nitrile group of albicidin into 
a position that favors nucleophilic attack of amide N25 on 
nitrile C28, leading to the formation of 2 (Figure 3D). By ex-
changing the threonine to a slightly bulkier valine, we 
strengthened the hydrophobic interactions between I95 
and the amino acid in position 99 (now V). This could lead 
to a more stable barrier and thus promote faster cyclization 
of albicidin. Accordingly, with the barrier largely removed 
in AlbAT99G, albicidin cyclization was almost abolished. In 
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agreement with this hypothesis, AlbAI95G showed reduced 
but still appreciable effects on albicidin (Figure 3C), since 
now merely the back-stop of the actual barrier was re-
moved. When incubated with the double mutant, Al-
bAI95G/T99G, albicidin was virtually unaffected (Figure 3C). 
The position of the side-chain of M131 appeared to pro-
tect the ketimine function of 2 from bulk solvent and to pre-
vent the formation of the hemiaminal 4a/b during hydroly-
sis of 2. In consequence, one would expect a mutation of the 
methionine to a residue with a less bulky side-chain to pro-
mote the formation of 3. Accordingly, AlbAM131A incubated 
with albicidin, led to a much larger percentage of 3 than the 
wt protein or any previously analyzed mutant (Figure 3C). 
We determined the complex structure of AlbAM131A with al-
bicidin at 2.2 Å (PDB ID 6hai) (Figure S19 and Table S1). In 
the structure, the small alanine side-chain affords ample 
room to form the hemiaminal intermediate (Figure S20). It 
should be noted that in the complex structure of AlbAwt with 
2, two ordered water molecules (HOH6 and 102) are in a 
position to attack the ketimine carbon (Figure S20) and may 
promote hydrolysis. 
Cyclization decreases albicidin activity, but AlbA is in-
sufficient to protect cells from albicidin 
An important question with respect to the resistance 
mechanism exerted by AlbA was whether the protein-medi-
ated modification altered albicidin activity. We attempted 
to purify 2 and 3 in sufficient quantities for biological 
testing by setting up large-scale conversion reactions. As ex-
pected, it was not possible to purify 2, as the peak converted 
to 3 during purification. Compound 3, on the other hand, 
was stable and we tested its activity against E. coli, Staphy-
lococcus aureus, Bacillus subtilis and Micrococcus luteus (Ta-
ble 1). The most pronounced effects were observed for E. 
coli and S. aureus, where 3 showed a decrease of activity by 
300 x and 222 x, respectively. For the other two strains, ac-
tivity was reduced by approximately two orders of magni-
tude. We have therefore been able to demonstrate that the 
modification of albicidin to 3 results in a significant de-
crease of albicidin activity. 
Table 1: Activity of 3 and 1 on selected bacterial strains. 
Cyclization of cyanoalanine to succinimide leads to a 
significant decrease in activity. 
  E.coli 
DSM1116 
S. au-
reus 
New-
man 
B. subtilis 
DSM10 
M. luteus 
DSM1790 
MIC 
(µg/mL) 
3 1.8 28.8 5.4 43.5 
1 0.006 0.13 0.03 0.5 
MIC shift 3/1 300 222 108 87 
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Figure 4 A MICs demonstrating that AlbAwt is insufficient to protect E.coli BL21 (DE3) from 1 or 7. Naturally occurring point-muta-
tion M131K on the other hand renders these cells albicidin resistant and protects the cells largely from 7. MICs are given as com-
pound concentrations (µg/mL) B Time-course for the cyclization of albicidin when incubated with AlbAwt (top) and AlbAM133Q (bot-
tom) using 1 : 1 protein : compound ratios. The M131Q point mutation leads to significantly accelerated cyclization. C Reevaluation 
of the albA sequence reveals an alternative start codon upstream of the reported start. Translation from the alternative start codon 
would yield an AlbA-L protein that also contains an N-terminal HTH motif followed by a random coil, analogous to TipA. D RT-qPCR 
results demonstrating that exposure of K. pneumoniae to 1, but not 7 induces albA transcription. 
It has been demonstrated in agar diffusion assays that 
when AlbA is pre-incubated with an equimolar amount of 
albicidin, the remaining concentration of free albicidin is 
too small to inhibit bacterial growth26. The same observa-
tion was made for the activity of DNA gyrase, the albicidin 
target, in vitro26. Since the read-out of these experiments is 
compound-protein affinity, we wondered if E.coli overex-
pressing AlbA would be resistant to albicidin. When we 
tested E.coli BL21 over-expressing AlbA, we found the cells 
to be susceptible to 1 (Figure 4A). Since Klebsiellae contain-
ing the albA gene are fully resistant to albicidin20-21, it thus 
appears highly probable that additional factors are required 
for albicidin resistance. 
Evolution of AlbA and evidence for a more efficient 
homolog in K. pneumoniae 
We aimed to understand how AlbA-mediated albicidin re-
sistance had evolved and how widely proteins that could 
potentially bind albicidin and related compounds are 
distributed amongst sequenced proteobacteria. A search of 
the non-redundant database for AlbA homologs returned 
1,906 sequences from beta-, gamma-, and delta-proteobac-
teria, all of which were annotated as mercuric ion resistance 
(MerR) family transcription regulators. Next, we used the 
AlbA-albicidin complex structure to define the residues in 
direct contact with albicidin and how each of these residues 
could be varied to still allow albicidin binding. This contact 
pattern (Figure S21) was then used to filter the obtained 
homologs. Phylogenetic analysis reveals that this pattern 
can occasionally be found in Klebsiella and Enterobacter 
species, as well as in several closely related sequences from 
Raoultella, Kosakonia, Kluyvera, Escherichia, Pseudoesche-
richia, and Leclercia spp.. The distribution of the relevant se-
quences in the phylogenetic tree (Figure S22) suggests that 
in Klebsiella and Enterobacter the pattern evolved on sev-
eral independent occasions, whereas in Rauoltella, Kosa-
konia, Kluyvera, Escherichia, Pseudoescherichia, and Lecler-
cia, close homology coupled with the virtual omnipresence 
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of sequences containing the contact pattern suggests intro-
duction of the protein into these species via horizontal gene 
transfer as a means of resistance against albicidin. Addition-
ally, the Raoultella branch is embedded into the Klebsiella 
branch, which suggests Klebsiella as the source of the hori-
zontal gene transfer into Raoultella. For other species, the 
phylogeny is not well resolved at the branching point, so the 
source of the transfer is more difficult to pinpoint. 
Since AlbA was originally discovered in K. oxytoca, we had 
a closer look at the evolution of AlbA in Klebsiellae as a 
whole. When searching for AlbA homologs in publicly avail-
able whole genome sequencing data and filtering identical 
sequences, two clades of AlbA were found: One group, con-
sisting mostly of K. oxytoca and K. michiganensis strains, is 
currently comprised of 36 sequences with no less than 90 
% homology to AlbA. These sequences contain no variations 
in the residues making contact with albicidin. The second 
group contains 129 sequences that are all 77  2 % identical 
to AlbA and is found mainly in K. pneumoniae, K. variicola, 
and K. quasipneumoniae. These sequences contain a single 
point mutation in the residues contacting albicidin. Here, 
the M131 residue, which has been identified by us as critical 
to shield the intermediate 2 from water, is mutated to either 
Q (most cases) or K (some instances). The exchange of 
M131 to a hydrophilic residue opened the possibility that 
these AlbA homologs would behave in a manner similar to 
AlbAM131A. We therefore introduced the point mutations 
M131Q and M131K into AlbAwt and analyzed the effects of 
these mutations on albicidin cyclization. Both mutants pro-
moted much faster cyclization of albicidin than the wild-
type protein (Figure 4B), with the lysin mutant being faster 
than the glutamine mutant. When the more prevalent mu-
tant M131Q was used at sub-stoichiometric concentrations 
it showed faster cyclization than AlbAwt (Figure S23). Inter-
estingly, we did not observe the same effect of pH on Al-
bAM131Q as AlbAwt, which may suggest that the glutamine 
now acts as a specific base to promote the reaction (Figure 
S23). We were curious whether these mutations altered the 
behavior of AlbA enough to now allow AlbA to protect cells 
from albicidin. When we tested E.coli over-expressing Al-
bAM131Q or AlbAM131K, we found the M131Q mutation to have 
no effect on the minimum inhibitory concentration (MIC) of 
albicidin. In stark contrast, cells overexpressing the M131K 
mutant were fully resistant to albicidin (Figure 4A). 
Whether this is a direct function of cyclization or involves 
additional factors will require further study. It thus appears 
as if a version of AlbA that is more efficient at protecting 
cells from albicidin already preexists in the microbial com-
munity and may be passed on to critical human pathogens 
via horizontal gene transfer. In fact, several instances of this 
point mutation can be found in AlbA homologs present in E. 
coli. 
AlbA defines a new TipA-like family 
One characteristic of the AlbA homologs from both clades 
described above was prominent: Virtually all possess an N-
terminal extension when compared to AlbA. This extension 
has homology to known HTH DNA-binding domains of tran-
scription factors and is followed by a coiled-coil region, af-
ter which homology to AlbA begins. The basic architecture 
of these AlbA homologs therefore resembles that of the au-
toregulatory TipA system, with a substrate binding domain 
that has been extended through internal gene duplication. A 
closer look at AlbA reveals the existence of an alternative in-
frame start codon that would lead to an N-terminal exten-
sion by a HTH-domain, followed by a coiled-coil region (Fig-
ure 4C). This observation was also noted by Rostock and 
colleagues26 and implies that the original annotation of the 
AlbA gene is incomplete. Analogously to TipA, two versions 
of AlbA may exist in cells: AlbA-L, capable of driving tran-
scriptional events after binding to albicidin and AlbA-S/Al-
bAwt, which removes free albicidin from cells (Figure 4C). In 
the TipA system, the S version is expressed at a > 20-fold 
excess when compared to the L version, presumably be-
cause far fewer DNA-binding protein copies (TipA-L) are re-
quired than those simply neutralizing the thiopeptide anti-
biotics (TipA-S)17. Interestingly, in the work describing the 
discovery of AlbA, it was noted that the minimal DNA frag-
ment providing albicidin resistance contained two gene 
products, which appeared to be under the control of one 
promotor18. They were believed to be two different pro-
teins, but their relative abundance roughly reflected the 1 : 
20 ratio observed for TipA-L and TipA-S and their molecular 
weights are in agreement with the predicted molecular 
weight of AlbA-L and the observed molecular weight of 
AlbA-S18. If this hypothesis were correct, exposure of albA-
positive bacteria to albicidin would be expected to induce 
transcription of AlbA. We thus treated albA-positive K. 
pneumoniae, which are fully resistant to albicidin and har-
bor the M131Q mutation, with albicidin and analyzed the 
transcription levels of AlbA-L and AlbA-S by RT-qPCR at dif-
ferent time-points (Figure 4D). 10 min after exposure, vir-
tually no change in AlbA transcription levels was detected, 
while transcription was upregulated ~ 60-fold 90 min after 
the addition of albicidin. After 4 h, transcription levels were 
upregulated ~3000-fold, indicating a very strong response 
to albicidin. These data suggest that AlbA acts in a manner 
similar to TipA, where binding of the effector molecule trig-
gers protein expression of the effector-binding protein. 
Since TipA is able to bind structurally diverse thiopep-
tides, we wondered if AlbAwt is also able to bind other com-
pounds, in particular cystobactamid. The KD of AlbAwt for an 
albicidin derivative with cystobactamid-like features (5, 
Figure S24) was reported as 14 nM based on a fluorescene 
quenching assay26. Yet despite this tight interaction, the an-
tibacterial effects of 5 were not neutralized by AlbA in agar 
diffusion assays and 5 did not stabilize AlbA in NMR exper-
iments26. SPR experiments using 7 and AlbAwt suggest a KD 
in the low µM range (Figure S25), which may reconcile af-
finity with NMR data and agar diffusion assay results. To 
probe the effect of AlbAwt on 7, we incubated it with protein 
to investigate if AlbAwt, AlbAT99V, AlbAM131A or AlbAM131Q 
were able to also promote the cyclization of cystobactamid 
(convert the central -methoxy-asparagine into an aspar-
timide). Even after extensive incubation times at 37 °C, we 
did not observe any modification of cystobactamid (Figure 
S25). When comparing the MICs of 1 and 7 for E.coli BL21 
and E.coli BL21 overexpressing AlbAwt, we found no differ-
ence, perhaps because the cells were extremely sensitive to 
both compounds (Figure 4A). The M131K mutant also pro-
vided protection against 7, but not to the same extent as 
against 1 (Figure 4A). Since albA-containing K. pneumoniae 
have an MIC against both compounds of > 64 µg mL-1, we 
investigated bacterial growth after addition of either 1 or 7 
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. While cultures continued to grow, only 7, but not 1, had a 
statistically significant negative effect on bacterial growth 
(Figure S25). Finally, we tested whether 7 was also able to 
induce an increase in AlbA copy numbers in K. pneumoniae 
by RT-qPCR. In striking contrast to 1, cystobactamid 919-2 
was unable to increase albA RNA copy numbers, even 4 h 
after the addition of compound (Figure 4D). These data hint 
that binding of 7 is insufficient to cause the dimerization of 
AlbA-L and thus drive transcription of the albA gene. We 
modelled the interaction of 7 and AlbAwt to rationalize the 
differences in binding between the two compounds (Figure 
S24). Which AlbA-independent resistance mechanism is 
employed by K. pneumoniae to protect against cystobac-
tamid will require further study. 
The internal gene duplication of the TipA-S-like antibiotic 
binding domain changes the architecture of the protein to 
allow binding of extended, hydrophobic antibiotics in a 
binding tunnel. This raises the question how wide-spread 
this new architecture actually is. When we analyzed all > 
3000 UniProt sequences listed in Pfam as containing TipA, 
we found that the duplication of the TipA-S region has oc-
curred exactly twice in the evolution of this family (Figure 
S26). One branch contains AlbA and related sequences, 
which are a colorful mixture of beta- and gamma-proteo-
bacteria and enterobacteria. Overall, this branch contains 
an assortment of TipA sequences with and without the in-
ternal gene duplication. Curiously, the second branch is 
very compact and contains exclusively TipA-like proteins 
with a duplication of TipA-S. All of these sequences are from 
Clostridiae, including C. botulinum, and part of a larger Clos-
tridium branch (Figure S26). They belong to the larger fam-
ily of MerR-type transcriptional regulators and also encode 
an N-terminal HTH domain, followed by a coiled-coil region, 
reflecting the TipA and AlbA architecture. It is completely 
unclear which extended, hydrophobic natural product is 
bound by the proteins belonging to the second branch, or 
which transcriptional events are triggered in Clostridiae 
upon exposure. 
Discussion 
The vast majority of currently used antibiotics have been 
isolated from microorganisms and modified for clinical ap-
plication. From an evolutionary standpoint it is intuitive to 
search in this space – microbes have evolved to secure and 
defend their ecological niche from other microbes, often us-
ing antibiotics as chemical weapons. But this also poses an 
inherent problem: if an antibiotic has been used for eons, it 
is only logical that defense strategies – antibiotic resistance 
– have also evolved. These resistance mechanisms then 
preexist in the microbial population and can be dissemi-
nated if a particular antibiotic finds broad use, for example 
in human antibiotic therapy. To circumvent this problem, 
rational compound design is required, which relies on a de-
tailed understanding of these mechanisms of resistance. In 
determining the structure of AlbA, we sought to enable the 
design of compounds circumventing AlbA-mediated re-
sistance. Unexpectedly, the structure revealed AlbA to be a 
member of the TipA family of multi-drug resistance auto-
regulatory systems. Consequently, the AlbA gene was 
reevaluated and an alternative upstream start codon found, 
which may give rise to AlbA-L and AlbA-S analogously to 
TipA. What transcriptional events may be controlled by 
AlbA-L will require further study. It is unclear if AlbA itself 
is a multi-drug resistance protein or merely evolved from 
such a system, since the AlbA system is not induced by the 
related cystobactamid. However, the observation that the 
internal gene duplication of the effector binding site leads 
to a complete change in binding-site architecture and pro-
vides a new antibiotic binding scaffold highlights the adapt-
ability of antibiotic resistance mechanisms. 
TipA is able to form a covalent complex with diverse thi-
opeptide antibiotics, which sequesters them from the cyto-
plasm and thus inactivates them. AlbA is unable to form a 
covalent bond with albicidin, but forms an exceptionally 
stable complex31 from which albicidin dissociates very 
slowly. In addition, we discovered that AlbA promotes the 
cyclization of albicidin, which leads to a loss of activity and 
decreased affinity. The mechanism of very tight binding 
combined with slow chemical modification may also be ben-
eficial for transcriptional control, since it allows elevated 
transcription to cede once exposure to albicidin is stopped. 
In AlbA, the combination of high-affinity binding with chem-
ical modification may be a way to approximate the benefi-
cial effect of the covalent TipA-thiopeptide bond. It also 
opens the possibility of acquired AlbA mutations, which 
lead to faster cyclization of albicidin and in turn a lower en-
ergetic burden on cells, since only sub-stoichiometric quan-
tities of AlbA-S would then be required. A first step in that 
direction may be the M131K mutation observed in K. pneu-
moniae. This underscores the importance of investigating 
resistance mechanisms in detail to accelerate the develop-
ments of new antibiotics circumventing preexisting re-
sistance mechanisms. 
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The structure of AlbA reveals it to be a new binding scaffold adapted to the sequestration of long-chain antibiotics and 
a member of the multi-antibiotic neutralizing TipA family. Unexpectedly, AlbA promoted the chemical modification of 
albicidin, which reduced albicidin potency. 
 
 
